Abstract:
Background: Pregnancy-induced hypertension (PIH) contributes significantly to adverse feto-maternal outcome in a developing nation like ours. Significant hypertension must be treated to reduce the possible risks. The threshold at which treatment needs to be initiated remains a big question, depending on priority for fetus or mother.
Aim: To compare the side effects of labetalol versus hydralazine given intravenously for control of pregnancy
induced hypertension.
Methodology: It was a Randomized Controlled trial in which total of 330 cases of age range 20-35 with >20
weeks of gestation with sustained severe hypertension participated through non- probability, Purposive sampling.
Informed consent taken and demographic information was recorded. Patients in group A were given an
intravenous bolus infusion of labetalol 20mg. Group B patients were given an intravenous hydralazine 5-10mg in bolus. Patients were followed for 60 minutes to observe the side effects of drug like by researcher. The results were noted on a specially designed performa.
Results: The mean age of females was 27.42±3.49 years. The mean gestational age of females at time of
presentation was 28.97±4.48weeks. The mean SBP of females was 109.44±16.92 mmHg while mean DBP was
77.29±14.74 mmHg. Total 135(40.9%) women developed maternal hypotension, out of which 27(16.36%) belongs to labetalol group while 108(65.45%) belong to hydralazine group and 55(16.67%). Women developed abnormal FHR, out of which 1(0.61%) belongs to labetalol group while 54(32.72%) belong to hydralazine group. The difference between both groups was highly significant.
Conclusion: Thus it was concluded that use of hydralazine was associated with more side effects in females with PIH as compared to labetalol. Now we have better drug to manage PIH with low rate of complications
